Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
437 Leser
Artikel bewerten:
(0)

AOP Orphan, AOP Orphan IP AG and orphanix GmbH join forces to develop RetinolX to prevent bronchopulmonary dysplasia

Dow Jones hat von Pressetext eine Zahlung für die Verbreitung dieser Pressemitteilung über sein Netzwerk erhalten.

Wien (pts037/13.05.2019/13:45) - AOP Orphan IP AG and AOP Orphan Pharmaceuticals 
AG have entered into a partnership with orphanix GmbH to jointly develop 
RetinolX, an innovative medicine for the prevention of Bronchopulmonary 
Dysplasia (BPD). 
 
BPD is a life-threatening lung disease affecting very preterm infants. Around 1 
% of births are very preterm and potentially affected by this severe disease. 
However, no authorized preventive medicine exists yet on a global level. The 
joint parties are collaborating closely with expert physicians in neonatal 
intensive care to develop a new solution to prevent this devastating lung 
disease. 
 
The project aims to deliver an EU-wide market authorization by Q1 2022 under the 
centralized authorization procedure. Financial terms were not disclosed. The 
collaboration includes rights to additional unspecified orphan conditions. 
 
"This cooperation is a perfect match, as orphanix, AOP Orphan IP AG and AOP 
Orphan are all passionately dedicated to creating new treatments for patients 
with severe rare conditions. In addition, we all offer strong specialized 
capabilities. We are thrilled about the partnership given the successful history 
and track record of AOP Orphan and AOP Orphan IP AG", explains Dr. Philipp 
Heinrich Novak, CEO and Founder of orphanix. 
 
"RetinolX will solve a high unmet medical need for the prevention of BPD across 
the globe", states orphanix Co-Founder Dr. Stefan Johansson, consultant 
neonatologist and Associate Professor in Paediatrics in Stockholm, Sweden. 
 
Dr. Rudolf Widmann, Founder and Chief Therapeutic Development Officer of AOP 
Orphan, adds "We are excited to work with orphanix to develop and commercialize 
this potentially life-changing treatment. Projects like this are the reason I 
founded AOP Orphan." 
 
Michael Steiger, Managing Director of AOP Orphan IP AG, points out that "the 
collaboration with orphanix opens a new therapeutic area for AOP Orphan IP AG 
and strengthens the company's focus on rare and severe diseases." 
 
About RetinolX 
Safe, effective and easy-to-administer: RetinolX is being developed as a 
parenteral medicinal product (IM/IV) based on Retinol (Vitamin A), specifically 
addressing the needs of very preterm infants in intensive care. Retinol is 
recommended for prevention of BPD in international neonatology guidelines. 
 
About Bronchopulmonary dysplasia (BPD) 
BPD is a life-threatening lung disease of very preterm and very low birthweight 
infants (<1,500g/<32 weeks at birth) potentially leading to long-term 
consequences. Around 1 % of births globally are very preterm and potentially 
affected by BPD. 
 
About AOP Orphan Pharmaceuticals AG 
AOP Orphan is a multinational company with headquarters in Vienna, Austria 
focusing on clinical research, development and distribution of medicines for 
rare and complex diseases. The company also provides individualized and 
customized services to meet and accommodate the needs of physicians and patients 
across Europe, the Middle East & Asia. Currently AOP Orphan is concentrating on 
orphan and complex diseases in HematoOncology, Cardiology & Pulmonology and 
Neurology & Metabolic Disorders. 
 
About AOP Orphan IP AG 
AOP Orphan IP AG is a member of the group of companies of AOP Orphan 
International AG with headquarters in Vaduz, Principality of Liechtenstein, the 
core activity of which is the acquisition, development and commercial 
exploitation of intellectual properties, mainly in the medical area. An 
increasingly growing importance lies in the research and development of medical 
and related technical products. 
 
About orphanix GmbH 
orphanix GmbH is a medical development company headquartered in Linz / Austria. 
In line with its mission of "Filling the blind spot in medicine", orphanix is 
dedicated to developing innovative solutions for high unmet medical needs in the 
rare disease space. orphanix has received orphan designations for prevention of 
neonatal diseases by EMA and FDA. 
 
Contacts 
 
AOP Orphan Pharmaceuticals AG 
Wilhelminenstrasse 91/IIf, 1160 Vienna, Austria 
Dr. Rudolf Widmann, Chief Therapeutic Development Officer 
E: publicaffairs@aoporphan.com 
I: http://www.aoporphan.com 
 
AOP Orphan IP AG 
Städtle 28, 9490 Vaduz, Principality of Liechtenstein 
Mr. Michael A. Steiger, Managing Director 
E: michael.steiger@maruag.li 
 
orphanix GmbH 
Lederergasse 18/1, 4020 Linz, Austria 
Dr. Philipp Heinrich Novak, Chief Executive Officer 
E: dr.no@orphanix.com 
I: http://orphanix.com 
 
(Ende) 
 
Aussender: AOP Orphan Pharmaceuticals Aktiengesellschaft 
Ansprechpartner: AOP 
Tel.: +43 503 72 44 24 
E-Mail: olena.weissenbacher@aoporphan.com 
Website: www.aoporphan.at 
 
Quelle: http://www.pressetext.com/news/20190513037 
 
 

(END) Dow Jones Newswires

May 13, 2019 07:45 ET (11:45 GMT)

© 2019 Dow Jones News
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.